Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4610684 | 1.00 | GPR119 (0.44) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL7496058 | 0.85 | GPR119 (0.51) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL25819373 | 0.85 | GPR119 (0.51) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL7497146 | 0.85 | GPR119 (0.51) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL4611160 | 0.85 | GPR119 (0.44) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL4611162 | 0.85 | GPR119 (0.44) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL28709765 | 0.84 | GPR119 (0.46) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL22764724 | 0.84 | GPR119 (0.46) | GPR119THRBGAASMN1; SMN2STS | |
| SCHEMBL4611042 | 0.83 | PPARA (0.41) | PPARA | |
| SCHEMBL31346211 | 0.83 | GPR119 (0.45) | GPR119THRBGAASMN1; SMN2STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641771-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | UCB PHARMA SA (BE) | 2008-10-15 | — | — | EP | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD22, CD2, DPP3 | GPR119 3790/4885THRB 2883/4885GAA 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.